Introduction
Primary cutaneous T-cell lymphomas (CTCLs) represent a heterogeneous group of lymphoproliferative disorders characterized by monoclonal proliferation of skin-homing CD4+ve T lymphocytes. (Willemze et al., 2005) The major variant is Mycosis Fungoides (MF), which is confined to the skin and has a slowly progressing course over years to decades. (Quaglino et al., 2012) The less common Sézary syndrome (SS) carries a worse prognosis and is characterized by erythroderma, generalized lymphadenopathy, and leukemic blood involvement with Sézary cells (Wilcox, 2014) .
Granulysin is a cytotoxic molecule expressed, together with granzymes and perforin, in granules of cytotoxic T lymphocytes (CTLs) and natural killer cells (NK). It was originally discovered in 1998 as an antimicrobial peptide, with subsequently described roles in innate immunity (cytolytic and pro-inflammatory), dendritic cell chemotaxis and activation (immune alarmin function) and functions in tumor immunology (inducing tumor cell lysis by apoptosis). (Wang, 2014) RESEARCH ARTICLE Early investigations showed that impaired expression of granulysin by NK cells correlates with progression of cancer and lower levels of granulysin expression denotes an immunosuppressive state in cancer bearing patients (Kishi et al., 2002) . Subsequent studies confirmed this observation (Nagasawa et al., 2005; Saigusa et al., 2007) . However in NK cell tumors, serum granulysin was found to be proportionately increased with cancer cell load in NK cell leukemia and was significantly reduced after treatment. (Sekiguchi et al., 2012) Based on these findings, some authorities suggested that granulysin level may be used as a marker for tumor prognosis. (Okada and Morishita, 2012) To the best of our knowledge, granulysin expression has not yet been investigated in CTCL.
Expression of Granulysin and FOXP3 in
Regulatory T cells (Tregs), characterized by a CD4+ CD25+ phenotype, represent 5% to 10% of peripheral T cells. They are defined as a T-cell population that can influence other lymphoid cells with suppression of the immune response. Tregs play an essential role in immune regulation by facilitating peripheral immune self-tolerance and thus precluding autoimmunity. (Zou, 2006) Tregs express the transcriptional repressor Forkhead box P3 (FOXP3) which is essential for their development and considered the most specific marker for them. (Zhan et al., 2012) .
Tregs play an important role in immune evasion by cancer cells, by suppression of cancer cell specific CTLs, thus helping cancer cells to escape immune surveillance. In keeping with this, several studies have showed that increased numbers of Tregs are associated with poor prognosis and decreased survival in several types of carcinoma. (Du et al., 2012; Zhang et al., 2012) However, an opposite role is played by these in cells in many hematological malignancies, including CTCL, where higher counts of FOXP3+ve Tregs were associated with improved survival and lower counts were associated with higher stage and more tumor burden. (Kelley and Parker, 2010) Moreover, down regulation of FOXP3 gene expression was linked to the progression of MF. (Johnson et al., 2014) However, the issue was complicated by many observations in CTCL, where large cell transformation in MF was associated with FOXP3 expression in the malignant large cells (Hallermann et al., 2007) , CTCL cells could be induced to express FOXP3 in vitro (Berger et al., 2005; Kasprzycka et al., 2008) , and the neoplastic cells in few reported CTCL cases were expressing FOXP3 (Gjerdrum et al., 2007; Clark, 2009; Heid et al., 2009; Marzano et al., 2009 ).
The present study aims to investigate the expression of granulysin and FOXP3 in MF and its precursor lesion large plaque parapsoriasis and its leukemic form SS.
Materials and Methods
The study was conducted on 58 patients (4 large plaque parapsoriasis, 48 MF and 6 SS), which were recruited and clinically diagnosed in Dermatology and Venereology Department, Tanta University Hospital and confirmed pathologically in Pathology Department, Faculty of Medicine, Tanta University. 4 mm punch biopsies were taken from the lesional skin of all patients. Biopsies were fixed in 10% neutral buffered formalin solution, processed and embedded in paraffin wax. The blocks were sectioned and stained routinely by Hematoxylin and eosin. Blocks showing less than 5 high power fields (x400) with lymphomononuclear infiltrate (per section) were excluded.
All selected blocks were immunohistochemically stained for FOXP3 and granulysin. For immunostaining, 4 μm sections were deparaffinized in xylene, and then rehydrated in descending concentrations of ethanol. Blockage of endogenous peroxidases (by incubation in 0.3% H 2 O 2 for 30 min) was followed by microwave treatment (15 min in 10 mM sodium citrate buffer pH 6.0) for antigen retrieval. Slides were then incubated with the primary antibodies FOXP3 (Mouse Anti-FOXP3 Monoclonal Antibody, Cat. #A00744, GenScript, USA, dilution 1:300 overnight at 4°C) and granulysin (Mouse Anti-granulysin IgG2b Monoclonal Antibody, Biotec, Monosan, Netherlands, dilution: 1:80 for 30 minutes at 25 o C). Specific binding was detected using the LSAB 2 kit (Dako, Carpentaria, CA, U.S.A.) according to the manufacturer's instructions. Sections were washed by phosphate buffered saline after each step. Phosphate buffered saline was used instead of the primary antibody as negative control.
Slides were examined blindly (without knowledge of the clinical data). Counting the positive cells was done by the use of LEICA image analysis system (LEICA DFC290 HD, Leica Microsystems Ltd., Heerbrugg, Switzerland). The fields that contained the infiltrate were determined by low power magnification (x100). Five high power fields (x400 fields) were counted in each case. Cells with nuclear positivity for FOXP3 and those with cytoplasmic positivity for granulysin were counted. The counts were statistically analyzed using SPSS version 16 (SPSS Inc., Chicago, Illinois, USA).
Results
The present study included 58 cases of CTCL formed of 54 cases of CTCL (48 MF and 6 SS) and 4 cases of its precursor large plaque parapsoriasis. Different stages of MF were included namely; patch stage (n=10), plaque stage (n=30), tumor stage (n=8) and SS (n=6). The study included 35 male patients and 23 females. The age ranged from 31-71 years with mean 48.9±9.29 years.
Granulysin immunohistochemistry
Granulysin positivity was cytoplasmic (figures 1-A to 1-D) and was detected in the reactive mononuclear cells. The mean counts for Granulysin in the different stages were represented in Table (1) . Granulysin positivity was higher in MF than in the precursor lesion (parapsoriasis en plaque) and higher in the more advanced stages of MF (p<0.001). In post-hoc test, all groups showed significant differences between each other except between tumor stage and SS (p=0.08). No significant difference was found between male and female cases as regards granulysin counts (p=0.85). :http://dx.doi.org/10.7314/APJCP.2015.16.13 
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FOXP3 immunohistochemistry:
FOXP3 positivity was nuclear and restricted to the reactive T cell population [no neoplastic cell positivity could be detected in all included cases] (figures 2-A to 2-D). The mean FOXP3 counts in the studied cases were summarized in Table ( 2). The mean FOXP3 count was higher in early stage MF [plaque and patch stages] than in the late tumor stage and Sézary syndrome (p<0.001). However, FOXP3 count was lower in the precursor lesion (parapsoriasis en plaque) than in other stages of MF. In post-hoc test: all the groups showed significant differences between each other except between parapsoriasis en plaque and SS (p=0.35) and between patch and plaque stages of MF (p=1). No significant difference was found between male and female gender as regard FOXP3 mean counts (p=0.72).
Correlation between FOXP3 and Granulysin counts:
A significant negative correlation between FOXP3 and granulysin counts were observed (r=-0.43, p=0.001), figure 3.
Discussion
Although the prognosis of CTCL is generally good, reliable markers are needed to identify the subset of patients at risk for a more aggressive course, including leukemic transformation. (Escher et al., 2006; Zhou et al., 2014) Multiple complex pathways are operable in the evolution of MF through the different stages, ending in leukemic or large cell transformation. These pathways involves the interaction between the neoplastic T cells and cells of the immune system (dendritic cells, cytotoxic T cells and Tregs), with the intermediary action of many cytokines. (Jawed et al., 2014) To the best of our knowledge, this is the first study to explore granulysin expression in CTCL. Granulysin expression was found to increase with progression of MF from the pre-lymphomatous phase (parapsoriasis en plaque) to the progressive phases of MF. This is well-explainable under the light of the immune alarmin function of Granulysin that activates antigen presenting DCs, which have a central role in the initiation and progression of CTCL (Edelson, 2001) . It has been reported that cross talk between malignant T cells and CTL, with the intermediary role of bacterial superantigens, shares substantially in CTCL progression. (Willerslev-Olsen et al., 2013) Granulysin is expressed in, and released on activation of, the CTL, and hence an intermediary role of granulysin, and its alarmin-like action on DC, in CTCL progression is strongly suggested. So, Granulysin may be the junction, in a vicious circle, between CTL and DC in CTCL for perpetuation and progression of the proliferation of the malignant T cells. Hence, granulysin may be a potentially useful marker for aggressive behavior as well as a therapeutic target in CTCL, a fact that should be further validated by correlation with the patient survival.
The role of CD4+ve CD25+ve FOXP3+ve Tregs in MF has been a matter of long controversy. Initially, the work of Berger et al. (2005) suggested that CTCL cells have a regulatory phenotype. Thereafter, FOXP3 expression by the neoplastic cells in CTCL was demonstrated in a series of 5 patients with large-cell transformation of MF. (Hallermann et al., 2007) However, this was soon selfcriticized by the lack of specificity of the utilized antibody. (Banham et al., 2008) Several other groups have provided evidence that FOXP3 expression is rare in the neoplastic population in CTCL and that FOXP3 expression is found mainly in the non-neoplastic Tregs (Klemke et al., 2006; Tiemessen et al., 2006; Gjerdrum et al., 2007; Capriotti et al., 2008; Solomon and Magro, 2008; Wada et al., 2010) In our study, there was no detectable FOXP3 positivity in the neoplastic T cells in any of the studied cases. This observation was in agreement with the results of Klemke et al. (2006) and Wada et al. (2010) . Rare examples of CTCL with convincing evidences of neoplastic cell expression of FOXP3 have represented SS (Capriotti et al., 2008; Heid et al., 2009; Wada et al., 2013) , aggressive epidermotropic CD8-positive cytotoxic T-cell lymphoma (Gjerdrum et al., 2007) or an extraordinary aggressive epidermotropic CD4+ medium-/large sized primary cutaneous T cell lymphoma (Marzano et al., 2009 ) rather than classic MF.
In the present study, higher counts of FOXP3 + Tregs were observed in the earlier stages of MF (plaque/ patch stages) than in the late tumor stage and SS. This is in keeping with the results of the most of the above mentioned studies of FOXP3 in CTCL (Klemke et al., 2006; Tiemessen et al., 2006; Gjerdrum et al., 2007; Capriotti et al., 2008; Solomon and Magro, 2008; Wada et al., 2010; Alcantara-Hernandez et al., 2014) . Moreover, Gjerdrum et al. (2007) found that increased number of Treg was associated with a better prognosis in CTCL (including MF and its leukemic variant SS). Another study showed that very low Treg counts were detected in SS, in both the cutaneous lesion and peripheral blood and even claimed that low counts of FOXP3+ Tregs distinguishes MF from SS. (Klemke et al., 2006) A molecular support for these findings was provided by the work of Johnson et al. (2014) , who found a decrease in the FOXP3 mRNA in skin samples with progression of MF stages.
It was proven that increasing Tregs counts in solid malignancies is associated with poorer prognosis; probably due to the suppressive effect of Tregs on CD8 +ve CTLs, responsible for the tumor immunity and killing of tumor cells. (Du et al., 2012; Zhang et al., 2012) The reverse was observed in many hematological malignancies, especially T cell lymphomas, including CTCL (Kelley and Parker, 2010) . This paradox in the prognostic significance of Tregs in CTCL compared to solid (non-hematologic) malignancies may be explained by the fact that Tregs not only suppress the anti-tumor immune response, but also have the potential to suppress tumor growth in malignant T cells as well.
However, Fried and Cerroni (2012) denied the progressive decrease of Tregs with progression of the MF lesion in sequential biopsies of 14 MF patients. They claimed that FOXP3 expression can be acquired or lost during the course of the disease, comparable to other phenotypic markers. Nevertheless, the low number of cases in thier study may weaken their conclusion.
No significant difference was found between patch and plaque stage of MF in our study. It should be noted that both stages are early stages of MF, with nearly similar prognosis (Jawed et al., 2014) , even prompting some authors to consider both stages as one entity during investigation for FOXP3 counts (Gjerdrum et al., 2007) .
In our study, the FOXP3 counts in the prelymphomatous large plaque parapsoriasis were significantly lower than the early stages of MF and very near to that of SS. This may apparently contrast with many studies showing higher counts in the non-neoplastic dermatoses in comparison to CTCL. (Fujimura et al., 2008; Solomon and Magro, 2008; Wada et al., 2010; Hanafusa et al., 2013) However, most of these studies did not include the prelymphomatous lesions in the non-neoplastic entities and also all used the percentage of the FOXP3+ cells rather than absolute counts (as was used in our study). One of these studies, examining FOXP3 counts in prelymphomatous lesions, found even lower counts in large plaque parapsoriasis than in the early stages of MF, agreeing with our results. The DOI:http://dx.doi.org/10.7314/APJCP.2015.16.13.5359 Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphomas and the Sézary Syndrome same study showed that reactive lymphomatoid conditions have higher Tregs counts than the prelymphomatous T cell dyscrasias. (Solomon and Magro, 2008) In the present study, the expression of granulysin, which is known to localize in the granular compartment of CTL, was inversely correlated to FOXP3 expression. This makes sense in the light of the negative effect of Tregs on CTLs, where upregulation of FOXP3 cells leads to down regulation of CTLs. This may be another mechanism by which FOXP3 +ve cells may affect progression of MF in addition to direct suppression of the neoplastic T cells, where Tregs may down regulate CTLs in the lesion, with loss of the alrmin effect of granulysin on DCs. This may lead to loss of the trophic effect of DC on the malignant T cells. When Tregs go down, this inhibitory effect is lost with the release of CTL activity, causing activation of DC and progression of malignancy. However, further mechanistic studies may be needed to substantiate this hypothesis.
In conclusion, the present study supports a role of granulysin in MF progression, with potential diagnostic and therapeutic implications, and proposes a novel hypothesis about the effect of FOXP3 +ve Tregs in the suppression of the activity of the neoplastic cells in MF.
